We have identified biomarker signatures for MoA, clinical response and toxicity prediction in industry partnerships
Partner | Indication | Clinical question | Technology | Tissue | #patients | Outcome and Status |
---|---|---|---|---|---|---|
COMPANY A | Solid tumors (tg T cells) | Prediction of therapy response | scRNA-seq | Infusion cell product | 14 | Correlation of r = 0.75 with measured response
Discovery project |
COMPANY B | Refractory rheumatoid arthritis | Treatment mode of action | scRNA-seq | Murine hind-limbs | 20 | 1.0 AUC Discovery project |
Release Therapeutics (MaxiVAX) | Solid tumors (cancer vaccine) | Prediction of therapy response and toxicity | FC, IHC, proteomics, etc. | PBMCs, serum, tumor | 20 | completed Discovery project |
Turnstone Biologics, US
| Solid tumors (TIL therapy) | Prediction of therapy response and toxicity | CITEseq, TCRseq | Infusion cell product, PBMCs | 55 | ongoing Discovery project |
COMPANY C | Autoimmunity
| Prediction of therapy response, toxicity, MoA
| CITE-seq, TCR-seq, FC
| PBMCs
| 40 | ongoing Discovery project |
COMPANY D | Cell therapy
| Prediction of manufacturing success
| CITE-seq
| PBMCs | 24 | completed Discovery project |